Lv1
40 积分 2025-09-30 加入
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
4天前
已完结
[Clinical pathway and expert consensus on the diagnosis and treatment of bone metastases from lung cancer (2025 edition)]
4天前
已完结
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
4天前
已完结
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases
4天前
已完结
Pathological Response, Tumor Microenvironment Dynamics, and Survival Dissociation after Neoadjuvant Chemoimmunotherapy for Lung Cancer with Rare Histological Subtypes
8天前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
8天前
已完结
Validation and refinement of the ninth edition ypN descriptor in patients with non−small cell lung cancer receiving neoadjuvant therapy
9天前
已完结
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
16天前
已完结
Cancer burden and control in China: landscape, trends and challenges
16天前
已完结
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
17天前
已完结
皖公网安备34019202002308
